Venus Remedies, on 20 September, announced receiving marketing approval from Serbia for its drug that is used in the treatment of cancer.

The company said in its regulatory filing that they have secured marketing authorisation from Serbia for gemcitabine and docetaxel, widely used chemotherapy drugs beneficial in the treatment of various types of cancer.

The company added, “With this, Venus Remedies has now secured a total of 511 marketing approvals for its oncology products across 66 countries.”

Aditi Chaudhary, president of international business at Venus Remedies, said that they have more than 40 marketing authorisations for its drug in South Eastern Europe and the Balkan region, including 9 approvals for oncology drugs. The marketing authorisation from Serbia is a significant achievement that will help improve access to affordable cancer drugs in the region.

The company is in the pharmaceutical production business and specialises in producing various formulations in the therapeutic segment, including antibiotics, critical care medicines, and oncology drugs.

In its quarterly report for the April-June quarter, the company reported an 82.87% YoY decline in its net profit at Rs 1.18 crore and a 33.49% YoY decline in its revenue from operations at Rs 95.15 crore.